AngioDynamics pairs a bullish technical breakout and a three-quarter earnings beat streak — with another print in just 10 days — against a business quality score that sits below the engine's floor and options positioning that is unusually skewed toward puts, making this a momentum-and-catalyst trade rather than a quality-driven one.
Thesis pillars
- Quality Below Floor↓Deteriorating
- Bullish Breakout Setup↓Deteriorating
- Earnings Beat Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
AngioDynamics, Inc. (ANGO) Stock Analysis
Inst Constrain edge
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $11.40: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
AngioDynamics is a medical device company offering vascular access, peripheral vascular and oncology products, including the Auryon atherectomy system, NanoKnife, AngioVac and AlphaVac. International distributors accounted for about 74% of its international revenues in fiscal... Read more
Sell if holding. Engine safety override at $11.40: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About AngioDynamics, Inc.
About AngioDynamics, Inc.
AngioDynamics organizes its portfolio into two segments: Med Tech - the Auryon atherectomy system, AlphaVac/AngioVac thrombectomy devices, and the NanoKnife ablation system - and Med Device, covering angiographic catheters, drainage products, and implantable ports. International revenue fell 21% in fiscal 2025 after the February 2024 divestiture of the PICC, Midline, dialysis, and BioSentry businesses. International distributors accounted for approximately 74% of the company's international revenue for the fiscal year ended May 31, 2025.
AngioDynamics sells its devices in the United States primarily through a direct sales force targeting interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists, and internationally through a mix of direct sales and third-party distributors in markets including China, Japan, Brazil, the Middle East, and Europe. Products are manufactured largely at two leased New York facilities in Queensbury and Glens Falls, supplemented by a supply agreement with Biomerics in Costa Rica and other third-party manufacturers; the company announced a restructuring in January 2024 to shift additional production to partners in Costa Rica, Latvia, Italy, Israel, and China, expected to complete in the third quarter of fiscal 2026. Revenue depends on hospital and physician reimbursement from Medicare, Medicaid, and private payors, and on maintaining contract positions with group purchasing organizations and integrated health delivery networks, which the filing notes increasingly compete on price. Competitors include Boston Scientific, Medtronic, Becton Dickinson, Stryker, and Teleflex.
Show full overview
A structural vulnerability the filing quantifies is AngioDynamics' reliance on single and limited-source suppliers for several key products, raw materials, and components - a dependency the company says it experienced firsthand during fiscal 2022 and 2023 supply disruptions - combined with a manufacturing transition that shifts production from its Queensbury, New York plant to third-party manufacturers across five countries by the third quarter of fiscal 2026. Layered on that transition risk is geographic sourcing exposure to China, where the 10-K warns that new tariffs or export restrictions could force AngioDynamics to raise prices or relocate manufacturing capacity, either of which the company says would compress gross margins if it cannot pass the costs through to customers.
See also: Healthcare · Medical Instruments & Supplies
From AngioDynamics, Inc.'s most recent 10-K filing, extracted October 11, 2026.
Recent developments
updated 2026-10-13Recent Developments — AngioDynamics, Inc.
Latest news
- NEWS AngioDynamics Stock Is Falling Thursday: What's Going On? — benzinga Oct 8, 2026 negative
- NEWS Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings — benzinga Oct 8, 2026 positive
- NEWS AngioDynamics Q1 2027 Earnings Call: Complete Transcript — benzinga Oct 8, 2026 neutral
- NEWS Earnings Scheduled For October 8, 2026 — benzinga Oct 8, 2026 neutral
- NEWS AngioDynamics Appoints Eric Honroth As President And CEO, Effective November 2 — benzinga Oct 8, 2026 positive
Generated 2026-10-13T11:37:16Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Unprofitable operations — net margin -10.1%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.40: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $10.60. Score 5.6/10, moderate confidence.
Take-profit target: $17.00 (+49.1% upside). Prior stop was $10.60. Stop-loss: $10.60.
Quality below floor (3.7 < 4.0).
AngioDynamics, Inc. trades at a P/E of N/A (forward -256.0). TrendMatrix value score: 9.1/10. Verdict: Sell.
10 analysts cover ANGO with a consensus score of 4.1/5. Average price target: $20.
What does AngioDynamics, Inc. do?AngioDynamics is a medical device company offering vascular access, peripheral vascular and oncology products,...
AngioDynamics is a medical device company offering vascular access, peripheral vascular and oncology products, including the Auryon atherectomy system, NanoKnife, AngioVac and AlphaVac. International distributors accounted for about 74% of its international revenues in fiscal 2025.